Treating a systemic disease as a local one: failure points of current pancreatic cancer management and a multimodal, biology-guided framework for redesign
- 1Triple Helix Science, Santa Ana, CA, United States
Abstract
Pancreatic ductal adenocarcinoma remains among the most lethal solid tumors, with 5-year survival near 13% despite decades of incremental change, and current management continues to be organized around anatomic resectability and a chemotherapy backbone applied largely without regard to tumor biology. This article advances the thesis that the dominant paradigm underperforms because it treats a systemic, molecularly convergent, multi-compartment disease as though it were a local one. We first summarize the real advances of the past decade—in surgery, systemic therapy, molecular profiling, and immunotherapy—and then identify five interlocking failure points that persist despite them: (i) selection by vessel anatomy, judged on imaging criteria that are read inconsistently and that classify inaccurately even where read consistently, and applied to splanchnic veins without accounting for their baseline variability and tumor-associated thrombosis; (ii) occult metastasis and the resulting limits of local cure for the systemic majority, evidenced by the gap between complete resection and durable survival and by early distant recurrence; (iii) the addition of radiotherapy, which improves local control without extending survival; (iv) chemotherapy chosen without reference to a validated prognostic classical/basal-like distinction, although prospective subtype-directed regimen selection has not yet improved outcomes in randomized testing; and (v) a sequential, non-integrated structure in which systemic and immune therapy are deferred and no definitive path exists for the roughly 80% who are not surgical candidates. We then propose a multimodal, biology-guided framework that answers each failure point, with every component graded on an explicit evidence scale: corrected tumor-suppressor gene therapy matched to lesion type, a systemic backbone combining renin-angiotensin system-pathway inhibition with immunogenically sequenced chemotherapy and personalized neoantigen vaccination, in-situ immune conversion of an accessible tumor by cryoablation with local priming and natural killer (NK) cell delivery, and front-end biological patient selection. The framework is conceptual rather than product-specific; we specify its rationale, its integration in time, a staged first-in-human development program, and the studies required to test it. The objective is to convert local disease into systemic benefit—a step the current paradigm is not designed to take.
Related
- Case Report: Multimodal treatment of pediatric H3G34-mutant diffuse hemispheric glioma: a safety and feasibility case report combining precision medicine and tumor treating fields with conventional care
- Potential Locations for Noninvasive Brain Stimulation in Treating Poststroke Deficits: Exploration From Multimodal Neuroimaging
- Skeletal Muscle Index, Tumor and Systemic Immunity, and Survival in Advanced Pancreatic Ductal Adenocarcinoma
- Case Report: Value of MR relaxometry and spectroscopy in multimodal imaging characterization of limbic encephalitis in systemic sclerosis
- Clinical Course and Management of Pancreatic Pseudocyst Perforation
BibTeX
@article{sewell2026treating,
title = {{Treating a systemic disease as a local one: failure points of current pancreatic cancer management and a multimodal, biology-guided framework for redesign}},
author = {Patrick E. Sewell},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1941793},
url = {https://doi.org/10.3389/fonc.2026.1941793},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Treating a systemic disease as a local one: failure points of current pancreatic cancer management and a multimodal, biology-guided framework for redesign
AU - Patrick E. Sewell
PY - 2026
DA - 2026/10/12
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1941793
UR - https://doi.org/10.3389/fonc.2026.1941793
AB - Pancreatic ductal adenocarcinoma remains among the most lethal solid tumors, with 5-year survival near 13% despite decades of incremental change, and current management continues to be organized around anatomic resectability and a chemotherapy backbone applied largely without regard to tumor biology. This article advances the thesis that the dominant paradigm underperforms because it treats a systemic, molecularly convergent, multi-compartment disease as though it were a local one. We first summarize the real advances of the past decade—in surgery, systemic therapy, molecular profiling, and immunotherapy—and then identify five interlocking failure points that persist despite them: (i) selection by vessel anatomy, judged on imaging criteria that are read inconsistently and that classify inaccurately even where read consistently, and applied to splanchnic veins without accounting for their baseline variability and tumor-associated thrombosis; (ii) occult metastasis and the resulting limits of local cure for the systemic majority, evidenced by the gap between complete resection and durable survival and by early distant recurrence; (iii) the addition of radiotherapy, which improves local control without extending survival; (iv) chemotherapy chosen without reference to a validated prognostic classical/basal-like distinction, although prospective subtype-directed regimen selection has not yet improved outcomes in randomized testing; and (v) a sequential, non-integrated structure in which systemic and immune therapy are deferred and no definitive path exists for the roughly 80% who are not surgical candidates. We then propose a multimodal, biology-guided framework that answers each failure point, with every component graded on an explicit evidence scale: corrected tumor-suppressor gene therapy matched to lesion type, a systemic backbone combining renin-angiotensin system-pathway inhibition with immunogenically sequenced chemotherapy and personalized neoantigen vaccination, in-situ immune conversion of an accessible tumor by cryoablation with local priming and natural killer (NK) cell delivery, and front-end biological patient selection. The framework is conceptual rather than product-specific; we specify its rationale, its integration in time, a staged first-in-human development program, and the studies required to test it. The objective is to convert local disease into systemic benefit—a step the current paradigm is not designed to take.
SN - 2234-943X
ER -